0001193125-26-182389
SEC filing营收与净利双位数增长，但Organic Revenue零增长，增长全靠并购与Contingents。
| 指标 | 本期 | 去年同期 | 同比 |
|---|---|---|---|
| Total revenues | $1,901M | $1,404M | +35.4% |
| Core commissions and fees | $1,783M | $1,342M | +32.9% |
| Profit-sharing contingent commissions | $97M | $43M | +125.6% |
| Income before income taxes | $533M | $427M | +24.8% |
| Income Before Income Taxes Margin | 28.0% | 30.4% | -240bps |
| Net income attributable to the Company | $426M | $331M | +28.7% |
| Diluted EPS | $1.06 | $1.15 | -7.8% |
| EBITDAC - Adjusted | $731M | $535M | +36.6% |
| EBITDAC Margin - Adjusted | 38.5% | 38.1% | +40bps |
| Operating cash flow | $262M | $213M | +23.0% |
| Free Cash Flow | $241M | $196M | +23.0% |
本季度营收增长35.4%主要由并购驱动，其中$435M来自无同比基数的收购，贡献了绝大部分增量。Organic Revenue零增长，显示内生业务停滞，主要受Litigation-Related Impact（$10M）和Specialty Distribution业务下滑拖累。Contingents同比大增125.6%至$97M，成为利润增长的关键引擎，受益于承保结果改善、保费增长及并购。
利润率方面，EBITDAC Margin - Adjusted同比+40bps至38.5%，主要得益于Contingents增长和费用杠杆，但被Acquisition/Integration Costs（$26M）部分抵消。GAAP口径下Income Before Income Taxes Margin下降240bps至28.0%，主要因Amortization（+118.9%）和Interest（+115.2%）大幅增加，反映了并购融资的财务负担。
盈利质量方面，经营现金流$262M同比增长$49M，但营运资本变动拖累$332M，主要因应收款项增加和应计负债减少。Free Cash Flow $241M，转化率约56.6%（FCF/Net Income），显示现金流生成能力尚可但受营运资本波动影响。
| 分部 | 营收 | 同比 | 经营利润 | 利润率 | 驱动 |
|---|---|---|---|---|---|
| Retail | $1,210M | +33.4% | $317M | 26.2% | 并购贡献$270M，Organic Revenue +1.0%，受Litigation拖累 |
| Specialty Distribution | $682M | +40.0% | $221M | 32.4% | 并购贡献$165M，Contingents大增$38M，Organic Revenue -2.0% |
Retail分部Organic Revenue +1.0%，增长受续保业务放缓、部分险种费率下降及specialty pharmacy consulting业务模式变更拖累。Specialty Distribution Organic Revenue -2.0%，主要因CAT财产险费率下降，但Contingents强劲增长推动整体表现。
| 项目 | 本期 | 上期/变化 |
|---|---|---|
| Cash and cash equivalents | $1,003M | -$76M |
| Total debt | $7,822M | +$209M |
| Goodwill | $15,076M | -$11M |
| Amortizable intangible assets, net | $4,782M | -$124M |
| Operating cash flow | $262M | +$49M |
| Capex | $21M | +$4M |
| Free Cash Flow | $241M | +$45M |
| FCF转化率（FCF/Net Income） | 56.6% | — |
总债务增加$209M至$7,822M，主要因回购动用循环信贷$225M。利息支出同比+115.2%至$99M，反映并购融资的债务负担。公司仍有$1,375M增量借款能力，流动性充足。
资本配置：
一次性异常项：
关注点：